BioXcel Therapeutics (BTAI) Director Susan Atkins Receives Award

What Happened Susan E. Atkins, a director of BioXcel Therapeutics, received a grant of 17,000 derivative shares (reported as an award) on August 12, 2026. The reported acquisition price is $0.00, so there was no immediate cash payment or proceeds reported for the grant. The filing treats the award as a derivative security rather than a market purchase or sale.

Key Details

• Transaction date: 2026-08-12; Form 4 filed: 2026-08-14 (within the normal reporting window).
• Security: derivative award of 17,000 shares listed at $0.00 (no immediate dollar value reported).
• Shares owned after the transaction: not provided in the supplied data.
• Footnote on vesting: the award vests 33% on the first anniversary of the grant date, with the remaining shares vesting in two equal annual installments on the second and third anniversaries, subject to continuous service.
• No indication of a 10b5-1 plan, tax withholding sale, or immediate sale of shares in the filing.

Context This is a compensation-style award to a board member; such grants typically vest over time and do not represent an immediate market purchase or sale. Because the award vests over three years, any future market impact would depend on vesting, possible exercise (if an option), and any subsequent sales — none of which are shown in this filing.